Forest Expects Namenda To Thrive Under Medicare Part D
This article was originally published in The Pink Sheet Daily
Large cash-paying contingent of patients and sizable nursing home population should bring benefit from Part D coverage, company notes.
You may also be interested in...
The firm blames supplementary studies – which found numerical improvement for the memantine cohort but failed to meet statistical significance – for the denial.
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.
The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.